Superior vs Temporal Laser Peripheral Iridotomy in Primary Angle Closure Suspects (PACS)

  • STATUS
    Recruiting
  • End date
    Jul 15, 2022
  • participants needed
    200
  • sponsor
    Sunnybrook Health Sciences Centre
Updated on 15 February 2021

Summary

Basic Study Design: Prospective, randomized, single-center, single-blinded study to compare dysphotopsias and pain recollection immediately 2 weeks, and 3 months after LPI in PACS patients who have a clear indication for bilateral LPI. Our null hypothesis is that there is no difference in dysphotopsia or pain levels by LPI position. Our alternate hypothesis is that there are more dysphotopsias superiorly and more pain temporally.

Description

The study objective is to describe the difference in the incidence of dysphotopsias and sensation of pain both immediately, 2 weeks and 3 months after superior or temporal LPI. The main primary outcome variable will be the presence of dysphotopsias and the recollection of pain graded by a standardized pain scale.

Stratified Block Randomization: 200 patients will be recruited from participating centre. For each patient, the order of the eye to be treated as well as the position of the LPI superior or temporal will be randomized.

Methods

Subjects: Patients included in the study will be patients referred for a glaucoma evaluation or in follow up at Sunnybrook Science Center who are diagnosed as PACS and have therefore an indication for bilateral LPIs.

Interventions: All patients eligible will be examined by the principal investigator, including a slit lamp assessment of the anterior segment, gonioscopy of the angle and stereoscopic optic nerve examination with a 78 Diopters lens. Intraocular pressure (IOP) will be measured with applanation tonometry. Patients will be assessed with a macular and optic nerve OCT to rule out glaucoma.

Only bilateral PACS patients will be included. One randomly selected eye will receive superior LPI while contralateral eye temporal LPI. At the 2 week and 3 month follow up visits patients will be asked about dysphotopsias in one or both eyes and their recollection of pain will be graded. Other distractors will be included in the questionnaire such as increased tearing sensation.

Laser peripheral iridotomy will be performed using neo-dynium:yttrium:aluminium-garnet laser after pretreatment with 2% pilocarpine and brimonidine 0.15%. Superior LPIs will be placed between the 11- and 1-o'clock positions such that they were covered completely by the upper eyelid; nasal/temporal LPIs will be placed between the 2- and 4-o'clock positions or the 8- and 10-o'clock positions such that they were completely clear of the lid margin. Preference will be given to iris crypts, avoiding iris vessels when possible. Laser peripheral iridotomies will be performed in both eyes during the same visit and will be confirmed to be patent after the procedure. Intraoperative data collected will include initial per-shot laser energy in milli joules, number of laser shots, and total laser energy in millijoules. All the patients will be treated with fluorometholone 0.1% eye drops QID for 5 days after surgery.

Data Collection: Laser treatment specifications will be noted for the amount in LPI positioning, number of applications, and amount of energy used. Other relevant patient information will also be noted such as best corrected visual acuity (BCVA), refractive error, IOP and presence of lens opacities along with the patients gender, age and ethnicity. These patients will be scheduled for follow up examination and IOP measurement at 2 weeks and 3 months after LPI procedure. On follow up a questionnaire will be given to patients assessing pain recollection and presence of dysphotopsias. Lid coverage of the LPI will also be noted.

Sample size and Justification:

The target sample size of 200 participants was selected to provide 80% power on an estimated incidence of 10.7% incidence of dysphotopsias after superior LPI versus 2.4% after temporal LPI with a 2-sided error at = .05. This was based on the study published by Vera et al,.2014. The sample size allows for a 15% loss to follow-up and a 10% crossover between randomization groups.

Data Analysis: Group differences in baseline variables will be evaluated using Student t test for continuous variables and chi-square tests for categorical variables. P values of less than 0.05 will be considered statistically significant.

Recruitment: Patients will be identified on initial or follow up visits at Sunnybrook Health Center. The ophthalmologists will identify potential subjects and the study coordinator will explain the nature of the study and invite them to participate. An Information and Consent Form will be signed by the patient previous to the enrollment in the study.

Details
Condition Primary Angle Glaucoma Closure Suspect
Treatment Yag Laser peripheral Iridotomy
Clinical Study IdentifierNCT04741919
SponsorSunnybrook Health Sciences Centre
Last Modified on15 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

clinical evidence of bilateral occludable angles (PACS) defined as
Peripheral anterior synechia (PAS) absent and trabecular meshwork not visible in 6 clock hours under non-indentation gonioscopy, Along with
absence of PAC or PACG, in both eyes
macular and optic nerve OCT within the 95% range of the normative database for patients to be included in this study

Exclusion Criteria

evidence of unilateral PACS
a history suggestive of an acute angle closure attack (based on symptoms) documented intraocular pressure over 30 mmHg
or any sign of Angle Closure Glaucoma (manifest glaucomatous neuropathy detected by OCT)
Patients with previous ocular surgeries will also be excluded
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note